Literature DB >> 6084947

Human T-cell leukemia virus: its discovery and role in leukemogenesis and immunosuppression.

G M Shaw, S Broder, M Essex, R C Gallo.   

Abstract

We have highlighted the events leading to the discovery of the first human RNA tumor virus and then reviewed what is currently known about its biology. From this, it is clear that we have only begun to appreciate the biologic diversity, the geographic distribution, and the disease spectrum of this family of human T-lymphotropic retroviruses which we collectively term HTLV. At a basic level, HTLV provides a unique opportunity to study in vitro and in vivo mechanisms of cell transformation. Given its close association with adult T-cell leukemia and its ability to efficiently immortalize primary cells in vitro, we believe that HTLV will very likely harbor clues to the biology of cell growth, differentiation, and transformation. At a more clinical level, the close association between HTLV and a malignancy of clonally expanded (HTLV-containing) mature T-cells argues strongly for a causal relationship, although the mechanism for such is currently unknown. It is likely that further study of the molecular and cellular biology of this virus will bring together these basic and clinical findings and elucidate, at least in part, one mechanism for human leukemogenesis. From a more speculative viewpoint, the role of HTLV in the pathogenesis of human disease appears even broader. As discussed in this chapter, there are indications that all subtypes of HTLV may produce immunosuppression both in vitro and in vivo, and there is now exciting new data to suggest that a novel member of this family of viruses, HTLV-III, is causally linked to the AIDS syndrome. Moreover, the possibility has been raised that the immunosuppressive properties of HTLV could predispose patients to non-T-cell malignancies as occurs in patients with AIDS or chemically induced immunosuppression. Finally, by employing the experimental strategies which were successful in isolating HTLV-I, HTLV-II, and HTLV-III, it may be possible in the future to identify still other human retroviruses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6084947

Source DB:  PubMed          Journal:  Adv Intern Med        ISSN: 0065-2822


  13 in total

1.  Seroprevalence of anti-HTLV I/II and anti-HIV-1 antibodies in a sample population in the Marche Region, Italy.

Authors:  F Mignini; L Quarenghi; S Cipriani; M Bartolucci; I Covelli
Journal:  Eur J Epidemiol       Date:  1994-12       Impact factor: 8.082

2.  Salivary antibodies as a means of detecting human T cell lymphotropic virus type III/lymphadenopathy-associated virus infection.

Authors:  D W Archibald; L I Zon; J E Groopman; J S Allan; M F McLane; M E Essex
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

3.  Immunological functions and phenotypes of peripheral blood lymphocytes from human T-cell leukemia virus-I carriers.

Authors:  Y Tanaka; S Oda; K Nagata; N Mori; H Sakamoto; S Eto; U Yamashita
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

Review 4.  Historical review of the causes of cancer.

Authors:  Clarke Brian Blackadar
Journal:  World J Clin Oncol       Date:  2016-02-10

5.  Enzyme immunoassay using a novel recombinant polypeptide to detect human immunodeficiency virus env antibody.

Authors:  R M Thorn; G A Beltz; C H Hung; B F Fallis; S Winkle; K L Cheng; D J Marciani
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

6.  Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection.

Authors:  R S Smith; R B Naso; J Rosen; A Whalley; Y L Hom; K Hoey; C J Kennedy; J A McCutchan; S A Spector; D D Richman
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

7.  Concomitant augmentation of CD4+ CD29+ helper inducer and diminution of CD4+ CD45RA+ suppressor inducer subset in patients infected with human T cell lymphotropic virus types I or II.

Authors:  R B Lal; D L Rudolph; D S Schmid; M D Lairmore
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

8.  Immunohistochemical localization of HTLV-I p19- and p24-related antigens in synovial joints of patients with rheumatoid arthritis.

Authors:  B Ziegler; R E Gay; G Q Huang; H G Fassbender; S Gay
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

9.  Development and maintenance of bovine cytotoxic lymphocytes with recombinant human interleukin-2.

Authors:  J Carter; N S Magnuson; W C Davis; P H Mason; J A Magnuson; J E Talmadge; P J Barr
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

10.  Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition.

Authors:  Murugesan Vanangamudi; Pramod C Nair; S E Maida Engels; Senthilkumar Palaniappan; Vigneshwaran Namasivayam
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.